Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sucrose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL9747719 | 1.00 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL6376479 | 1.00 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL367818 | 0.99 | CDK1 (0.73) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL10405566 | 0.99 | CDK1 (0.73) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL5972243 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL9704445 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL1001769 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL15656196 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL3797240 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL1272574 | 0.97 | CDK1 (0.71) | CDK1CCNB1CA2CA9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370098-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | Celator Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | claimed |
| EP-4370099-A1 | METHODS FOR PREPARING LIPOSOMAL FORMULATIONS | Celator Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | claimed |
| EP-4309657-A2 | REMOTE LOADING OF SPARINGLY WATER-SOLUBLE DRUGS INTO LIPOSOMES | Celator Pharmaceuticals, Inc. (US) | 2024-01-24 | — | — | EP | claimed |
| EP-4218739-A2 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | The Regents of The University of California (US) | 2023-08-02 | — | — | EP | claimed |
| US-20230059528-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | claimed |
| WO-2023288103-A1 | METHODS FOR PREPARING LIPOSOMAL FORMULATIONS | CELATOR PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | claimed |
| WO-2023288100-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | CELATOR PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | claimed |
| WO-2022115488-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-06-02 | — | — | WO | claimed |
| US-20220160644-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-26 | — | — | US | claimed |
| US-20200383929-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-10 | — | — | US | claimed |
| EP-3735250-A1 | SCALE UP SYNTHESIS OF SILICASOME NANOCARRIERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-11 | — | — | EP | claimed |
| US-10765636-B2 | Mesoporous silica nanoparticles with a lipid bilayer coating for cargo delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-08 | — | — | US | claimed |
| US-10722467-B2 | Remote loading of sparingly water-soluble drugs into liposomes | ZONEONE PHARMA, INC. (US) | 2020-07-28 | — | — | US | claimed |
| US-20190314282-A1 | REMOTE LOADING OF SPARINGLY WATER-SOLUBLE DRUGS INTO LIPOSOMES | Jazz Pharmaceuticals Therapeutics, Inc. | 2019-10-17 | — | — | US | claimed |
| US-20190160015-A1 | MESOPOROUS SILICA NANOPARTICLES WITH A LIPID BILAYER COATING FOR CARGO DELIVERY | UNIV CALIFORNIA (US) | 2019-05-30 | — | — | US | claimed |
| US-10004759-B2 | Remote loading of sparingly water-soluble drugs into lipid vesicles | ZONEONE PHARMA, INC. (US) | 2018-06-26 | — | — | US | claimed |
| US-12005142-B2 | Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof | TAIWAN LIPOSOME CO., LTD. (TW) | 2024-06-11 | — | — | US | disclosed |
| WO-2024111564-A1 | COMBINATION MEDICINE COMPRISING LIPOSOME COMPOSITION HAVING TOPOTECAN OR SALT THEREOF ENCAPSULATED THEREIN AND DNA DAMAGE REPAIR INHIBITOR | 富士フイルム株式会社 | 2024-05-30 | — | — | WO | disclosed |
| EP-1746976-A1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | Hermes Biosciences, Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005107712-A1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | HERMES BIOSCIENCES, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059528-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | BCL6, BCL3, BCL2L1 | CDK1 1764/4885CCNB1 483/4885CA2 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.